iPrevent®: a tailored, web-based, decision support tool for breast cancer risk assessment and management
Open Access
- 24 February 2016
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 156 (1) , 171-182
Abstract
We aimed to develop a user-centered, web-based, decision support tool for breast cancer risk assessment and personalized risk management. Using a novel model choice algorithm, iPrevent® selects one of two validated breast cancer risk estimation models (IBIS or BOADICEA), based on risk factor data entered by the user. Resulting risk estimates are presented in simple language and graphic formats for easy comprehension. iPrevent® then presents risk-adapted, evidence-based, guideline-endorsed management options. Development was an iterative process with regular feedback from multidisciplinary experts and consumers. To verify iPrevent®, risk factor data for 127 cases derived from the Australian Breast Cancer Family Study were entered into iPrevent®, IBIS (v7.02), and BOADICEA (v3.0). Consistency of the model chosen by iPrevent® (i.e., IBIS or BOADICEA) with the programmed iPrevent® model choice algorithm was assessed. Estimated breast cancer risks from iPrevent® were compared with those attained directly from the chosen risk assessment model (IBIS or BOADICEA). Risk management interventions displayed by iPrevent® were assessed for appropriateness. Risk estimation model choice was 100 % consistent with the programmed iPrevent® logic. Discrepant 10-year and residual lifetime risk estimates of >1 % were found for 1 and 4 cases, respectively, none was clinically significant (maximal variation 1.4 %). Risk management interventions suggested by iPrevent® were 100 % appropriate. iPrevent® successfully integrates the IBIS and BOADICEA risk assessment models into a decision support tool that provides evidence-based, risk-adapted risk management advice. This may help to facilitate precision breast cancer prevention discussions between women and their healthcare providers.Keywords
Funding Information
- National Health and Medical Research Council (1064244)
- ANZ Breast Cancer Trials Group
This publication has 31 references indexed in Scilit:
- Oophorectomy after Menopause and the Risk of Breast Cancer in BRCA1 and BRCA2 Mutation CarriersCancer Epidemiology, Biomarkers & Prevention, 2012
- Online Tool to Guide Decisions forBRCA1/2Mutation CarriersJournal of Clinical Oncology, 2012
- 16. The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010British Journal of Cancer, 2011
- Prophylactic mastectomy for the prevention of breast cancerCochrane Database of Systematic Reviews, 2010
- Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation CarriersJNCI: Journal of the National Cancer Institute, 2009
- The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensionsBritish Journal of Cancer, 2008
- Verification and validation of a project collaboration toolAutomation in Construction, 2008
- Mammographic Density and the Risk and Detection of Breast CancerNew England Journal of Medicine, 2007
- A breast cancer prediction model incorporating familial and personal risk factorsStatistics in Medicine, 2004
- Bilateral Prophylactic Mastectomy Reduces Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: The PROSE Study GroupJournal of Clinical Oncology, 2004